Sanofi (SNY) Capital Expenditures (2009 - 2021)

Sanofi has disclosed Capital Expenditures across 5 years of filings, most recently posting -$101.4 million for Q4 2021.

• Capital Expenditures for Q4 2021 came in at -$101.4 million, up 3.84% year-over-year; the trailing twelve-month figure through Dec 2021 was $653.3 million (changed N/A YoY), and the FY2025 annual result was $4.1 billion, up 20.63% from the prior year.
• Capital Expenditures came in at -$101.4 million for Q4 2021 at Sanofi, up from -$105.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$90.5 million in Q4 2019 to a low of -$105.4 million in Q4 2020.
• The 3-year median for Capital Expenditures is -$101.4 million (2021), against an average of -$99.1 million.
• Across the five-year window, Capital Expenditures fell 16.41% in 2020 and advanced 3.84% in 2021, its largest moves.
• Sanofi's Capital Expenditures stood at -$90.5 million in 2019, then declined by 16.41% to -$105.4 million in 2020, then gained by 3.84% to -$101.4 million in 2021.
• The last three Capital Expenditures figures came in at -$101.4 million (Q4 2021), -$105.4 million (Q4 2020), and -$90.5 million (Q4 2019), per Business Quant data.